Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3246)
All Articles published online
|
Publishing Process of This Article
|
May 6, 2022 (publication date) through May 7, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Herold Z, Herold M, Herczeg G, Fodor A, Szasz AM, Dank M, Somogyi A. High plasma CD40 ligand level is associated with more advanced stages and worse prognosis in colorectal cancer. World J Clin Cases 2022; 10(13): 4084-4096 [PMID: 35665117 DOI: 10.12998/wjcc.v10.i13.4084] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v10/i13/4084.htm |
| Number | Citing Articles |
| 1 |
Shanshan Ding, Xiaohan Dong, Xingguo Song. Tumor educated platelet: the novel BioSource for cancer detection. Cancer Cell International 2023; 23(1) doi: 10.1186/s12935-023-02927-5
|
| 2 |
Matjaz Rokavec, Elif Özcan, Jens Neumann, Heiko Hermeking. Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer. Cancer Research Communications 2023; 3(8): 1689 doi: 10.1158/2767-9764.CRC-22-0489
|
| 3 |
Hiroshi Fujimoto, Soichiro Fukuzato, Kazuki Kanno, Taisuke Akutsu, Hironori Ohdaira, Yutaka Suzuki, Mitsuyoshi Urashima. Reduced Relapse-Free Survival in Colorectal Cancer Patients with Elevated Soluble CD40 Ligand Levels Improved by Vitamin D Supplementation. Nutrients 2023; 15(20): 4361 doi: 10.3390/nu15204361
|
| 4 |
Cheng-Zhe Jian, Li Lin, Chia-Lang Hsu, Yu-Hsin Chen, Chiun Hsu, Ching-Ting Tan, Da-Liang Ou. A potential novel cancer immunotherapy: Agonistic anti-CD40 antibodies. Drug Discovery Today 2024; 29(3): 103893 doi: 10.1016/j.drudis.2024.103893
|
| 5 |
Juan Zhang, Lei Wang, Shuyi Li, Xuefeng Gao, Zhong Liu. CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy. Cancer Cell International 2022; 22(1) doi: 10.1186/s12935-022-02630-x
|